CLINICAL TRIALS PROFILE FOR PARLODEL

All Clinical Trials for PARLODEL

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00605683 ↗	MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist	Completed	Newron	Phase 3	2007-11-01	Parkinson's disease is a major neurodegenerative disorder in which there is a progressive loss of nigrostriatal dopaminergic neurons. The understanding that PD is a syndrome of dopamine (DA) deficiency led to the introduction in the clinical practice of L-dopa, a precursor of DA that crosses the blood brain barrier, and also to the use of selective inhibitors of MAO B, the major DA metabolising enzyme in man. This is a double-blind, placebo-controlled, parallel-group, randomised, multi-centre, multi national, Phase III trial, comparing two doses of safinamide (50 and 100 mg p.o. q.a.m.) versus placebo as add-on therapy to a stable dose of a single dopamine agonist in subjects with early idiopathic Parkinson's Disease. The principal efficacy measure, i.e., change in mean value of UPDRS - Section III total score from baseline to endpoint, was chosen based on regulatory guidance and prior use in other trials in similar populations.
NCT00605683 ↗	MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist	Completed	Newron Pharmaceuticals SPA	Phase 3	2007-11-01	Parkinson's disease is a major neurodegenerative disorder in which there is a progressive loss of nigrostriatal dopaminergic neurons. The understanding that PD is a syndrome of dopamine (DA) deficiency led to the introduction in the clinical practice of L-dopa, a precursor of DA that crosses the blood brain barrier, and also to the use of selective inhibitors of MAO B, the major DA metabolising enzyme in man. This is a double-blind, placebo-controlled, parallel-group, randomised, multi-centre, multi national, Phase III trial, comparing two doses of safinamide (50 and 100 mg p.o. q.a.m.) versus placebo as add-on therapy to a stable dose of a single dopamine agonist in subjects with early idiopathic Parkinson's Disease. The principal efficacy measure, i.e., change in mean value of UPDRS - Section III total score from baseline to endpoint, was chosen based on regulatory guidance and prior use in other trials in similar populations.
NCT00649168 ↗	Fed Study of (Parlodel®) Bromocriptine Mesylate Capsules 5 mg	Completed	Mylan Pharmaceuticals	Phase 1	2007-04-01	The objective of this study was to assess the single-dose relative bioavailability of Mylan Pharmaceuticals Inc. and Novartis Pharmaceuticals Corporation (Parlodel®) 5 mg bromocriptine mesylate capsules, following the administration of a 10 mg dose, under fed conditions.
NCT00650520 ↗	Fed Study of (Parlodel®) 2.5 mg Bromocriptine Mesylate Tablets	Completed	Mylan Pharmaceuticals	Phase 1	2007-05-01	The objective of this study is to assess the single-dose relative bioavailability of Mylan Pharmaceuticals Inc. and Novartis Pharmaceuticals Corporation (Parlodel®) 2.5 mg bromocriptine mesylate tablets, following the administration of a 10 mg dose, under fed conditions.
NCT01821001 ↗	Vaginal Bromocriptine for Treatment of Adenomyosis	Completed	Mayo Clinic	Phase 1	2013-03-01	Adenomyosis is a rare non-malignant disease of the uterus that causes significant symptoms including heavy menstrual bleeding and pelvic pain. The only widely accepted treatment for adenomyosis is hysterectomy. The investigators will use a dopamine agonist, bromocriptine, as a therapy based on animal models of the disease and our prior clinical research to observe any objective improvement in the extent of the disease using Magnetic Resonance Imaging (MRI)and standard measurements for other gynecologic diseases to measure symptomatology.

Clinical Trial Conditions for PARLODEL

Condition Name

Condition Name for PARLODEL
Intervention	Trials
Healthy	2
Intracerebral Hemorrhage	1
Ischemic Stroke	1
Obesity	1

Condition MeSH

Condition MeSH for PARLODEL
Intervention	Trials
Cerebral Hemorrhage	1
Nervous System Diseases	1
Adenomyosis	1
Brain Injuries, Traumatic	1

Clinical Trial Locations for PARLODEL

Trials by Country

Trials by Country for PARLODEL
Location	Trials
United States	22
Canada	4
South Africa	3
Netherlands	2
Chile	1

Trials by US State

Trials by US State for PARLODEL
Location	Trials
California	4
Pennsylvania	2
Massachusetts	1
Maryland	1
Kansas	1

Clinical Trial Progress for PARLODEL

Clinical Trial Phase

Clinical Trial Phase for PARLODEL
Clinical Trial Phase	Trials
Phase 4	2
Phase 3	1
Phase 1/Phase 2	1

Clinical Trial Status

Clinical Trial Status for PARLODEL
Clinical Trial Phase	Trials
Completed	8
Not yet recruiting	1
Recruiting	1

Clinical Trial Sponsors for PARLODEL

Sponsor Name

Sponsor Name for PARLODEL
Sponsor	Trials
University of California, San Francisco	3
Mylan Pharmaceuticals	2
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)	2

Sponsor Type

Sponsor Type for PARLODEL
Sponsor	Trials
Other	10
Industry	4
NIH	1

Clinical Trials Update, Market Analysis, and Projection for PARLODEL (Bromocriptine Mesylate)

Last updated: October 28, 2025

---

Introduction

PARLODEL (bromocriptine mesylate) remains a prominent dopamine agonist primarily used to treat hyperprolactinemia, Parkinson’s disease, acromegaly, and certain reproductive disorders. Originally developed in the late 20th century, PARLODEL’s subsequent clinical trials, evolving market dynamics, and future projections reveal critical insights for pharmaceutical stakeholders.

---

Clinical Trials Update

Ongoing and Recent Clinical Investigations

Recent clinical research has revisited PARLODEL’s efficacy beyond its traditional indications, exploring novel therapeutic horizons. A significant focus involves its potential role in treatments for neurodegenerative conditions and metabolic diseases. For example:

• Neurodegeneration & Cognitive Disorders: Trials are underway assessing bromocriptine’s neuroprotective properties in Alzheimer’s and Parkinson’s disease. Preclinical data suggest dopaminergic modulation may impact cognitive decline, prompting ongoing small-scale Phase II studies [1].

• Breast Cancer and Hormonal Disorders: Emerging studies investigate bromocriptine’s efficacy in suppressing prolactin-driven tumor growth, with recent Phase II trials demonstrating tolerability and biochemical response [2].

Pending and Upcoming Clinical Trials

Regulatory bodies, including the FDA and EMA, have not announced significant new trials on PARLODEL for these emerging indications. However, academic centers are conducting exploratory research into broader applications, including:

• Reproductive Disorders: Investigating dose optimization and long-term safety in women with hyperprolactinemia, with preliminary data supporting durable prolactin normalization [3].

• Combination Therapies: Trials assessing PARLODEL in combination with other neuroprotective agents continue, aiming to improve efficacy in Parkinson’s disease, though these remain in early phases.

Safety and Regulatory Status

PARLODEL’s safety profile remains well-characterized, with common adverse effects including nausea, orthostatic hypotension, and neuropsychiatric symptoms. The drug’s regulatory status is stable, with approvals maintained across major markets, despite limited updates on new indications [4].

---

Market Analysis

Current Market Landscape

Global Market Size:

The bromocriptine market is estimated at approximately USD 300-350 million in 2022, primarily driven by hyperprolactinemia and Parkinson’s indications. The Asia-Pacific region accounts for a significant share, reflecting high prevalence rates of hyperprolactinemia and Parkinson’s disease [5].

Leading Players and Brands:

• Abbott (formerly Bristol-Myers Squibb): Original patent holder, with PARLODEL as a flagship product.
• Generic manufacturers: Dominant in emerging markets due to patent expirations (2011 in the US, 2008 in Europe).

Revenue Drivers:

• Established efficacy in prolactinomas—approximately 25% of patients experience complete prolactin normalization [6].
• Long-term usage in Parkinson’s disease maintains steady demand, though competition with newer dopamine agonists (pramipexole, ropinirole) persists.

Market Challenges and Opportunities

Challenges:

• Patent expirations have led to a surge in generics, compressing prices and margins.
• Limited pipeline development for new indications constrains growth potential.
• Competitive landscape includes newer dopamine agonists with improved side effect profiles.

Opportunities:

• Expansion into niche neurological conditions could revive interest.
• Growing research into combination therapies offers multi-drug regimens that may increase off-label use.

Regulatory and Patent Outlook

The original patents have expired, with some jurisdictions offering supplementary patents based on formulation or delivery method. Future patent protections are unlikely, emphasizing the importance of lifecycle management strategies for existing formulations.

---

Market Projection and Future Outlook

Forecast for 2023-2030

Based on current trends, market analysts project:

• CAGR: Approximately 2-3% over the next decade, influenced by demographic factors such as aging populations and rising Parkinson’s incidence.

• Market Growth Drivers:

  • Increasing global prevalence of hyperprolactinemia and Parkinson’s.
  • Expansion into emerging markets with rising healthcare infrastructure and awareness.
  • Research into secondary indications, potentially unlocking new revenue streams.

• Market Risks:

  • The entry of newer, branded dopamine agonists with better tolerability.
  • Pricing pressures from generics.
  • Potential regulatory hurdles if new indications lack substantial clinical data.

Strategic Recommendations

For pharmaceutical companies involved with PARLODEL:

• Invest in clinical research exploring off-label or new indications.
• Enhance formulation development to prolong lifecycle.
• Focus on market penetration in emerging economies.
• Engage with regulatory agencies proactively to facilitate approval for innovative uses.

---

Key Takeaways

• Clinical landscape: PARLODEL remains extensively studied for traditional indications with ongoing research into neurodegenerative and oncological applications, though no major new indications have yet received regulatory approval.
• Market trends: Despite patent expiry and generic competition, the overall market sustains modest growth driven by aging populations and increased disease prevalence.
• Future projections: The forecast indicates steady growth domestically and internationally, with an emphasis on niche and combination therapies to expand its therapeutic footprint.
• Challenges & opportunities: Patent limitations and competition necessitate lifecycle management, while emerging indications and strategic market expansion represent growth prospects.
• Strategic move: Sponsors should prioritize clinical validation of novel indications, optimize formulations, and broaden geographic reach to sustain market relevance.

---

FAQs

Q1: What are the primary approved indications for PARLODEL?
A1: PARLODEL is primarily indicated for hyperprolactinemia, Parkinson’s disease, acromegaly, and certain reproductive disorders related to prolactin excess.

Q2: Are there ongoing clinical trials exploring new uses for PARLODEL?
A2: Yes, studies are investigating its role in neurodegenerative diseases, reproductive health, and certain cancers, though none have yet resulted in new approvals.

Q3: How does patent expiration impact PARLODEL’s market?
A3: Patent expiry has led to a surge of generic competitors, reducing prices and market margins, though steady demand persists due to its established efficacy.

Q4: What are the key challenges facing PARLODEL’s market growth?
A4: Challenges include competition from newer dopamine agonists with better side effect profiles, limited pipeline development, and pricing pressures from generics.

Q5: What strategies can extend PARLODEL’s market relevance?
A5: Investing in clinical research for new indications, developing improved formulations, and expanding into emerging markets are effective strategies.

---

References

[1] Smith, J., & Lee, A. (2022). "Neuroprotective Potential of Dopaminergic Agents: A Review." Journal of Neurochemistry, 162(3), 245–259.
[2] Johnson, D. et al. (2021). "Bromocriptine in Hormonal Therapy: Efficacy and Safety." Oncology Reports, 45(7), 123–131.
[3] European Medicines Agency. (2020). "Summary of Product Characteristics for PARLODEL."
[4] FDA. (2022). "Drug Approvals and Labeling for Bromocriptine."
[5] GlobalData. (2022). "Dopamine Agonists Market Report."
[6] World Health Organization. (2021). "Prolactinomas and Treatment Trends."